EUVIMEDEUVIMED entdecken
Crossref

A Hybrid-Targeting Nanoparticle for Penetrable Delivery of Temozolomide to Enhance Glioblastoma Therapy

Guanru Wang, Hao Guo, Mengxin Wei, Ying Wang, Zengcai Jin, Jing Zhou, Jun He iD, Yaping Li iD

Nano Letters · 14.05.2025 · 25 (19) · 7989-7997

DOI: 10.1021/acs.nanolett.5c01609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Letters, online erschienen am 06.05.2025. Verfasst von Guanru Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai 201203, P.R. Chin…. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Nanoparticles, Brain Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy for glioblastoma (GBM) has not achieved the desired outcome due to inefficient blood-brain barrier (BBB) penetration and limited tumor-specific drug accumulation. Strategies that employ bioinspired nanoparticles to enhance targeted drug accumulation can help improve therapeutic efficacy. In this work, a novel nanoparticle, PCM@TMA-lip, exhibiting hybrid-targeting capabilities, is presented, with an engineered cell membrane coated on a lipid core. The membrane modified with a biologically derived peptide enables PCM@TMA-lip to evade immune clearance and enable precise tumor targeting. The lipid core with docosahexaenoic acid (DHA)-conjugated Temozolomide (TMZ) enhances FABP7-mediated uptake, promotes lysosomal escape via lipid peroxidation, and reduces tumor migration and drug resistance. In vitro, PCM@TMA-lip inhibited tumor cell malignancy and suppressed the growth of 3D spheroids. In vivo, it suppressed tumor progression, reduced Ki67+ proliferation, increased TUNEL+ apoptosis, and prolonged survival in GBM-bearing mice, highlighting its potential as an effective strategy to improve GBM chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaNanoparticlesBrain NeoplasmsAntineoplastic Agents, AlkylatingAnimalsHumansMiceCell Line, TumorBlood-Brain BarrierApoptosisDocosahexaenoic AcidsCell ProliferationDrug Delivery Systems

Stichwörter der Autor:innen

chemotherapydrug deliveryglioblastomatumor-specific drug accumulationtumor-suppressive effects

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingDocosahexaenoic Acids

Autor:innen und Institutionen

  • National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai 201203, P.R. China.
  • State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P.R. China.
  • Department of Anesthesiology, Shanxi Provincial People's Hospital, Taiyuan 030000, P.R. China.
  • School of Chinese Materia Medical Nanjing University of Chinese Medicine, Nanjing 210023, P.R. China.
  • Department of Oncology, Shanxi Province Academy of Traditional Chinese Medicine, Shanxi Province Hospital of Traditional Chinese Medicine, Taiyuan 030012, P.R. China.
  • Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Shandong 264000, P.R. China.

ORCID-Profile: Jun He, Yaping Li

Förderung

  • National Key Research and Development Program of China
  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China
  • Special Fund for Science and Technology Innovation Teams of Shanxi Province
  • Special Fund for Science and Technology Innovation Teams of the Administration of TCM of Shanxi Province
  • Shandong Laboratory Program

Zitieren

APA

Wang, G., Guo, H., Wei, M., Wang, Y., Jin, Z., Zhou, J., He, J., & Li, Y. (2025). A Hybrid-Targeting Nanoparticle for Penetrable Delivery of Temozolomide to Enhance Glioblastoma Therapy. Nano Letters, 25(19), 7989-7997. https://doi.org/10.1021/acs.nanolett.5c01609

Vancouver

Wang G, Guo H, Wei M, Wang Y, Jin Z, Zhou J, et al. A Hybrid-Targeting Nanoparticle for Penetrable Delivery of Temozolomide to Enhance Glioblastoma Therapy. Nano Letters. 2025;25(19):7989-7997. doi:10.1021/acs.nanolett.5c01609

BibTeX
@article{Wang2025,
  author = {Wang, Guanru and Guo, Hao and Wei, Mengxin and Wang, Ying and Jin, Zengcai and Zhou, Jing and He, Jun and Li, Yaping},
  title = {A Hybrid-Targeting Nanoparticle for Penetrable Delivery of Temozolomide to Enhance Glioblastoma Therapy},
  journal = {Nano Letters},
  year = {2025},
  volume = {25},
  number = {19},
  pages = {7989--7997},
  doi = {10.1021/acs.nanolett.5c01609}
}
Kostenlos starten →